Finance Watch: Biopharma IPOs Defy Broader Stock Performance Trends
Executive Summary
Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.
You may also be interested in...
Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
Merck KGaA Tightens Focus With Allergopharma Sale
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
IPO Update: Gottlieb’s Resignation Pulls Down Five Of Eight Newly Public Biopharmas
There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.